Business
Faron Appoints Interim Chief Medical Officer
Faron Appoints Interim Chief Medical Officer.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n\nFaron Pharmaceuticals Ltd.\n (\"Faron\" or the \"Company\")\n \nFaron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer\n \n· Dr. Marie-Louise Fjällskog, outgoing CMO, is proposed to continue key role in bexmarilimab's development as a Board member\n \nCompany announcement, September 21, 2023 \n \nTURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the appointment of Dr. Birge Berns, MD, as the Company's interim Chief Medical Officer (CMO). Dr. Berns will be based in the UK and her appointment is effective starting September 22, 2023.\n \nDr. Berns succeeds Dr. Marie-Louise Fjällskog, who is stepping down from her current CMO role at Faron. The Board of Directors have proposed to the Extraordinary General Meeting of the Company convened for tomorrow, Friday, September 22, 2023, that Dr. Fjällskog would be nominated to the Company's Board of Directors in a Non-Executive Director role. In this new role as a Non-Executive Director, Dr. Fjällskog would continue to play an integral role in the development of Faron's wholly owned immunotherapy asset, bexmarilimab, providing her clinical and regulatory expertise to support the Company's progress. \n \nDr. Berns is a seasoned senior pharmaceuticals executive with a background in oncology, clinical medicine, rheumatology and immunology. She brings more than 25 years' experience from senior leadership roles in global pharmaceutical companies, including Sanofi Aventis and Johnson & Johnson.\n \n\"I am delighted to welcome Birge to Faron as the interim Chief Medical Officer as we progress our ambitious clinical development program for bexmarilimab,\" said Dr. Markku Jalkanen, Chief Executive Officer of Faron. \"With her extensive experience in oncology clinical development, her business acumen and broad scientific and medical knowledge, she is exceptionally well qualified to advance our plans and progress development of what we hope will be the first macrophage-targeting immunotherapy for patients with aggressive hematological malignancies.\n \n\"I am also very pleased that Faron will continue to benefit from the support of Marie-Louise, in her proposed ...